

## ICH Progression: Minimum, Preferred, and Optional Dataset Recommendations.

Dataset	Minimal	Preferred	Optional
<b>Demographics</b>	<ul style="list-style-type: none"> <li>Age</li> <li>Sex</li> </ul>	<ul style="list-style-type: none"> <li>Ethnicity</li> </ul>	
<b>Index event, Acute Therapies &amp; Baseline function</b>	<ul style="list-style-type: none"> <li>Interval from onset to admission</li> <li>Admission GCS</li> <li>Any acute surgical intervention</li> <li>Type of acute surgical intervention</li> <li>Haemostatic therapy (and subtype)</li> <li>Acute BP lowering therapy</li> <li>Anticoagulant reversal</li> <li>Osmotic therapy (and subtype)</li> </ul>	<ul style="list-style-type: none"> <li>Pre-morbid mRS</li> <li>Baseline NIHSS</li> <li>Pre-stroke dementia</li> </ul>	<ul style="list-style-type: none"> <li>Temperature on admission</li> <li>Systolic BP</li> <li>Diastolic BP</li> <li>Interval from stroke onset to initiation of BP-lowering therapy</li> <li>Interval from initiation of BP-lowering therapy to guideline target BP</li> <li>Guideline target BP achieved &lt;1 hour</li> <li>SBP reduction &gt;70mmHg &lt;1 hour</li> </ul>
<b>Medical History</b>	<ul style="list-style-type: none"> <li>Diabetes Mellitus</li> <li>Previous ICH</li> <li>Hypertension</li> </ul>	<ul style="list-style-type: none"> <li>Prior ischaemic stroke</li> <li>Smoking status</li> <li>Hyperlipidaemia</li> <li>Height &amp; weight (to calculate BMI)</li> <li>Prior history of coronary artery disease</li> </ul>	<ul style="list-style-type: none"> <li>AF</li> <li>Prior ischaemic stroke</li> </ul>
<b>Medication Use (pre-event)</b>	<ul style="list-style-type: none"> <li>Antiplatelet</li> <li>Anticoagulant</li> </ul>	<ul style="list-style-type: none"> <li>Statin</li> </ul>	
<b>Baseline Imaging†</b>	<ul style="list-style-type: none"> <li>Interval from onset to imaging</li> <li>Interval from onset to subsequent scan(s)</li> <li>ICH location</li> <li>ICH Volume on initial and subsequent imaging</li> <li>IVH</li> </ul>	<ul style="list-style-type: none"> <li>Multiple ICH</li> <li>CHARTS location</li> <li>Radiological markers of haematoma expansion (e.g. Spot sign)</li> <li>Haematoma shape (irregular, spheroid)</li> <li>GRAEB Score</li> <li>Perihaematoma oedema volume on diagnostic scan</li> <li>Perihaematoma oedema volume on subsequent brain scan(s)</li> <li>Subarachnoid haemorrhage on diagnostic scan</li> <li>Subdural haemorrhage on diagnostic scan</li> <li>CAA diagnostic criteria met using Boston<sup>26</sup> or Edinburgh<sup>14</sup> Criteria (+/- individual components e.g. CMBs, siderosis)</li> </ul>	

<p><b>Outcomes*</b></p>	<ul style="list-style-type: none"> <li>• Functional outcome (mRS)</li> </ul>	<ul style="list-style-type: none"> <li>• Recurrent ICH</li> <li>• Ischaemic stroke</li> <li>• Myocardial infarction</li> <li>• All-cause death</li> <li>• Cardiovascular death</li> <li>• MACE‡</li> <li>• Non-cardiovascular death</li> <li>• Dementia</li> <li>• Cognitive impairment</li> <li>• Other neuropsychiatric symptoms (e.g. depression and anxiety)</li> </ul>	
<p>The interval from index event to biomarker measurement is considered a minimum dataset item. † Information regarding the imaging modality used should always be collected. * For each outcome, the time interval between index event and outcome should be reported. ‡ It is recommended that MACE should always at a minimum include the individual components of recurrent non-fatal stroke (ischaemic or ICH), non-fatal myocardial infarction, and cardiovascular death. AF, atrial fibrillation; BP, blood pressure; CAA, cerebral amyloid angiopathy; CHARTS, Cerebral Haemorrhage Anatomical Rating Instrument;; CMBs, cerebral microbleeds; CT, computerised tomography; GCS, Glasgow Coma Scale; ICH, intra-cerebral haemorrhage; IVH, intra-ventricular haemorrhage; MACE, major adverse cardiovascular and cerebrovascular events; MRI, magnetic resonance imaging; mRS, modified Rankin scale; NIHSS, National Institute for Health Stroke Scale.</p>			